Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Five Cancers Added  to List of Smoking-Related Diseases

July 1, 2004
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 13 No 7
Volume 13
Issue 7

WASHINGTON-The 2004 US Surgeon General’s report on the health risks of smoking adds five cancers to the list of diseases caused by cigarettes-acute myeloid leukemia, and stomach, pancreatic, cervical, and kidney cancers. Other newly

WASHINGTON—The 2004 US Surgeon General’s report on the health risks of smoking adds five cancers to the list of diseases caused by cigarettes—acute myeloid leukemia, and stomach, pancreatic, cervical, and kidney cancers. Other newly listed diseases are abdominal aortic aneurysm, cataracts, periodontitis, and pneumonia.

Published 40 years after the first Surgeon General’s report on smoking and health, which documented the evidence that cigarettes cause cancer of the lung and larynx in men and chronic bronchitis, Health Consequences of Smoking concludes that cigarettes cause disease in almost every organ, at every stage of life.

"In addition to cancer, cardiovascular, and respiratory diseases, and reproductive effects, the 2004 report documents many other damaging effects of smoking," said Surgeon General Richard H. Carmona, MD. The report estimates that 440,000 Americans die each year from smoking-related diseases and notes that smokers reduce their life expectancy by 13.2 years for males and 14.5 years for females. Beginning with the 2004 report, the Surgeon General’s office will indicate the strength of the evidence supporting a causal link between cigarette smoking and disease by using four categories. The cancers in each category are:

■ Sufficient to infer a causal relationship: lung, laryngeal, oral cavity and pharyngeal, esophageal, pancreatic, bladder and kidney, cervical, and gastric cancers, and acute myeloid leukemia.

■  Suggestive but not sufficient to infer a causal relationship: noncardia gastric, colorectal, and liver cancers.

■  Inadequate to infer the presence or absence of a causal relationship: ovarian.

■  Suggestive of no causal relationship: prostate, adult brain, and breast cancers.

The report omitted several cancers—lymphomas and multiple myeloma, and cancers of the skin, bone, and testicles—because they have not been linked to smoking. It also found that "the evidence is sufficient to infer that current smoking reduces the risk of endometrial cancer in postmenopausal women."

Major Conclusions

Health Consequences of Smoking is the first comprehensive assessment since 1990 of the evidence that indicts active cigarette smoking as a hazard to health. "We’ve known for decades that smoking is bad for your health, but this report shows that it is even worse," Dr. Carmona said. The report reached several major conclusions about cigarettes in addition to listing the new diseases attributed to smoking as a cause:

■  Smoking harms nearly every organ of the body, causing many diseases and reducing the health of people who smoke in general.

■  Quitting smoking has immediate as well as long-term benefits, reducing the risk of diseases caused by smoking and improving health in general.

■ Smoking cigarettes with lower machine-measured yields of tar and nicotine provides no clear benefit to health.

Changes in Smoking

The report notes that significant changes have occurred in cigarette smoking in the United States in the 4 decades since then-Surgeon General Luther Terry, MD, released his groundbreaking report on smoking and health. Among them:

■  There has been a broad reduction in society’s acceptance of smoking, which accompanied the growing awareness of tobacco’s dangers.

■  Per capita adult consumption of cigarettes has dropped from its peak of 4,345 annually in 1963 to 1,979 in 2002.

■  The number of former smokers today is greater than the number of current smokers.

■ Cigarette smoking was once a rite of passage for most teens. Today, only about half of high school seniors have ever smoked a cigarette, and about one in four is a current smoker.

The report calls for a sustained effort against smoking, a comprehensive approach to reducing tobacco use, and continued scientific research to address a number of tobacco-related health issues.

Such factors as smoking in motion pictures, the enormous advertising and promotional efforts of cigarette companies, and the belief by some that the smoking problem has been solved support the need to continue antismoking efforts, particularly among children and adolescents, the Surgeon General said.

Finally, the report emphasizes the need for research that further delineates the adverse health effects of tobacco use, improves the efficiency of tobacco surveillance and epidemiology, devises strategies to eliminate tobacco-related health disparities, and provides better prevention and treatment of addiction.

Articles in this issue

Long-Term Raloxifene Reduces Breast Ca Risk
Five Cancers Added  to List of Smoking-Related Diseases
Weekly Paclitaxel Superior to Conventional Schedule in Metastatic Breast Cancer Patients
Autologous Vaccine Delays TTP in Renal Cell Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


Pembrolizumab Combo Receives Canadian Approval in Cervical Cancer

Pembrolizumab Combo Receives Canadian Approval in Cervical Cancer

Russ Conroy
July 23rd 2025
Article

Data from the phase 3 KEYNOTE-A18 trial support the approval of the pembrolizumab-based regimen for those with stage III to IVA cervical cancer in Canada.

Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


Pembrolizumab Combo Receives Canadian Approval in Cervical Cancer

Pembrolizumab Combo Receives Canadian Approval in Cervical Cancer

Russ Conroy
July 23rd 2025
Article

Data from the phase 3 KEYNOTE-A18 trial support the approval of the pembrolizumab-based regimen for those with stage III to IVA cervical cancer in Canada.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.